Competitive Assay Patents (Class 435/7.93)
-
Publication number: 20140162891Abstract: The subject invention concerns methods using a panel of proteins to detect, diagnose, and monitor therapy during treatment of ovarian cancer in a female patient. The proteins were identified using proteomics analyses of plasma samples obtained preoperatively from ovarian cancer patients versus those of healthy control women. Such a panel has utility for the diagnosis of ovarian cancer, screening for ovarian cancer and possibly therapeutic monitoring.Type: ApplicationFiled: July 22, 2013Publication date: June 12, 2014Inventors: Rebecca SUTPHEN, Johnathan Mark LANCASTER
-
Publication number: 20140154257Abstract: Present invention is directed to materials and methods useful in diagnosing gut derived advanced glycation end-products (“Fru-AGEs”) associated with asthma, juvenile arthritis and other pro-inflammatory chronic diseases. Fru-AGEs arise from the interaction [fructosylation] between elevated gastro-intestinal excess free fructose and other food/bio-molecules including peptides, proteins, lipids, lipo/glycoproteins and others in the digestive tract. Such Fru-AGEs may further interact with moieties of the systemic circulation of those at risk [fructose malabsorbers], i.e. with acute phase proteins, heat shock proteins, immunoglobulins, esRAGE, and sRAGE. Specification describes methods to identify and/or make such excess-free-fructose derived immunogens, i.e.Type: ApplicationFiled: June 3, 2013Publication date: June 5, 2014Inventor: Luanne Robalo DeChristopher
-
Patent number: 8722342Abstract: A method for enhancing measurement sensitivity or avoiding hemoglobin influence in a latex agglutination or metal agglutination immunoassay method of a target antigen in a biological sample that uses calixarene in the immunoassay.Type: GrantFiled: July 3, 2009Date of Patent: May 13, 2014Assignee: Sekisui Medical Co., Ltd.Inventors: Mitsuaki Yamamoto, Akiko Suzuki
-
Publication number: 20140128320Abstract: The present invention relates to methods and compositions for treating and diagnosing disorders related to energy metabolism and the OST-PTP signaling pathway involving gamma-carboxylase, osteocalcin and adiponectin. Such disorders include, but are not limited to, metabolic syndrome, glucose intolerance, diabetes types 1 and 2, atherosclerosis and obesity.Type: ApplicationFiled: September 19, 2013Publication date: May 8, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Gerard KARSENTY, Patricia F. DUCY
-
Patent number: 8697368Abstract: Disclosed is a diagnostic marker for lung cancer comprising Hp?R as an active ingredient. Because blood, which is relatively easy to sample, is employed as a specimen, the diagnostic kit and marker for lung cancer is very simple and does not subject patients to a load compared to conventional methods that are directed to a biopsy. In addition, the kit and marker of the present invention is useful in the early diagnosis of lung cancer thanks to its high diagnostic sensitivity and selectivity.Type: GrantFiled: June 29, 2011Date of Patent: April 15, 2014Assignee: Paichai University-Academic Cooperation FoundationInventor: Il Han Kim
-
Patent number: 8691517Abstract: A sensor for the detection or measurement of a carbohydrate analyte in fluid comprises components of a competitive binding assay the readout of which is a detectable or measurable optical signal retained by a material that permits diffusion of the analyte but not the assay components, the assay components comprising: a carbohydrate binding molecule labelled with one of a proximity based signal generating/modulating moiety pair; and a carbohydrate analogue capable of competing with the analyte for binding to the carbohydrate binding molecule, the carbohydrate analogue being a flexible water-soluble polymer comprising: polymerized or co-polymerised residues of monomer units, the monomer unit residues bearing pendant carbohydrate or carbohydrate mimetic moieties and pendant moieties which are the other of the proximity based signal generating/modulating moiety pair.Type: GrantFiled: December 6, 2006Date of Patent: April 8, 2014Assignee: Medtronic Minimed, Inc.Inventors: Jesper Svenning Kristensen, Klaus Gregorius, Casper Struve, Yihua Yu
-
Publication number: 20140093865Abstract: Methods of determining whether an analyte is present in a sample using a competitive assay are provided. Aspects of the methods include employing a competitor that provides for the obtainment of signal which is directly proportional to the amount of analyte in the sample. Also provided are devices and kits that find use in practicing the methods described herein.Type: ApplicationFiled: September 10, 2013Publication date: April 3, 2014Inventors: Eric Espinosa, Andrew Farmer
-
Patent number: 8685662Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.Type: GrantFiled: March 30, 2007Date of Patent: April 1, 2014Assignees: Institut Pasteur, Universite Pierre et Marie Curie (Paris 6)Inventors: Sylviane Pied, Vincent Guiyedi, Pierre-André Cazenave, Maryvonne Kombila, Youri Chanseaud
-
Patent number: 8685714Abstract: This invention describes a quantitative, inexpensive, disposable immunosensor that requires no wash steps and thus generates no liquid waste. Moreover, in preferred embodiments of the sensor no timing steps are required of the user, and the sensor can be readily adapted to antigen-antibody interactions over a wide kinetic range.Type: GrantFiled: April 22, 2004Date of Patent: April 1, 2014Assignee: Universal Biosensors Pty LtdInventors: Alastair Hodges, Ron Chatelier
-
Patent number: 8679763Abstract: Human EEF2K genes are identified as modulators of the PTEN/AKT pathway and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT comprising screening for agents that modulate the activity of EEF2K are provided.Type: GrantFiled: March 10, 2006Date of Patent: March 25, 2014Assignee: Exelixis, Inc.Inventors: Arthur Brace, Robert A. Blake, Lori S. Friedman, Lynn Margaret Bjerke, Kevin M. Ward, Susana Nieto-Bergman
-
Patent number: 8663910Abstract: A plurality of kinds of liquids, which are of at least three kinds, containing (a) a test body solution containing at least one kind of an analyte, and (b) at least two kinds of liquids selected from the group consisting of a reagent solution, an amplifying solution, and a detecting solution, are fed to a detection site containing a specific binding substance with respect to the analyte. A qualitative analysis or a quantitative analysis of the analyte contained in the test body solution is thereby performed. Directions of liquid feeding of all of the plurality of the kinds of the liquids vary from one another, and the plurality of the kinds of the liquids are caused to intersect with one another at the detection site.Type: GrantFiled: September 18, 2009Date of Patent: March 4, 2014Assignee: FUJIFILM CorporationInventors: Mikinaga Mori, Junichi Katada, Hiroyuki Chiku, Takayoshi Oyamada
-
Patent number: 8663944Abstract: A method for differentiation of osteoarthritis from rheumatoid arthritis and non-disease conditions in a sample, comprising measuring in the sample the concentration of human cartilage intermediate layer protein 2 (CILP-2) in body fluids and more specifically, measuring in the sample the concentration of the N-terminal part of CILP-2 (2C1) or fragments thereof.Type: GrantFiled: August 17, 2010Date of Patent: March 4, 2014Assignee: AnaMar ABInventors: Pilar Lorenzo, Tore Saxne, Dick Heineg{dot over (a)}rd
-
Publication number: 20140057299Abstract: Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Ronghui Lin
-
Publication number: 20140057300Abstract: Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Ronghui Lin
-
Publication number: 20140057302Abstract: Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
-
Publication number: 20140057301Abstract: Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
-
Publication number: 20140057298Abstract: Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
-
Publication number: 20140057303Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
-
Publication number: 20140057304Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
-
Publication number: 20140057305Abstract: Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
-
Publication number: 20140057306Abstract: Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
-
Publication number: 20140057297Abstract: Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and paliperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
-
Publication number: 20140051098Abstract: The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility; and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer.Type: ApplicationFiled: April 8, 2013Publication date: February 20, 2014Applicant: W2 Holdings, Inc.Inventor: W2 Holdings, Inc.
-
Publication number: 20140051099Abstract: The present patent application relates to a method for diagnosing angioedema with a gain-of-function mutation of kinin formation, and for determining the amount of BK or des-Arg9 -BK antagonist required for halting the effects of angioedema, from a plasma sample of a patient. The invention also relates to a kit for said determination.Type: ApplicationFiled: April 12, 2012Publication date: February 20, 2014Applicants: CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE, UNIVERSITE JOSEPH FOURIER (GRENOBLE 1)Inventors: Christian Drouet, Samuel Luyasu, Arije Ghannam
-
Publication number: 20140030718Abstract: Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a veterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a B. pseudomallei-associated condition, such as melioidosis. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a B. pseudomallei-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by B. pseudomallei, such as meliodosis.Type: ApplicationFiled: March 14, 2013Publication date: January 30, 2014Applicant: The Board of Regents of the Nevada System of Higher Education, on Behalf of the University of NInventor: The Board of Regents of the Nevada System of Higher Education, on Behalf of the University of Nevada
-
Publication number: 20140024057Abstract: Testing systems and methods are disclosed for detecting a pregnancy marker of an animal. A test kit may include a first standard with a first concentration of the marker, a second standard with a second concentration of the marker lower than the first concentration, and at least three test surfaces coated with a biomolecular recognition element selected to bind with the marker. The test may also include a reagent solution with a conjugated biomolecular recognition element that binds with the marker, and a visual indicator that produces a visually detectable change when reacting with the conjugated biomolecular recognition element bound to each test surface. A detectable change generated by the marker from the sample with an intensity greater than the first concentration yields a pregnant result, lower than the second concentration yields a not pregnant result, and between the first and second concentrations yields a retest result.Type: ApplicationFiled: September 23, 2013Publication date: January 23, 2014Applicant: BIOTRACKING, LLCInventors: Charles W. PASSAVANT, Joshua R. BRANEN, Robert Garth SASSER, Jeremy Michael HOWARD
-
Publication number: 20140024056Abstract: The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens.Type: ApplicationFiled: February 10, 2012Publication date: January 23, 2014Applicant: President and Fellows of Harvard CollegeInventors: Michael Chorev, Joes A. Halperin
-
Patent number: 8628933Abstract: The invention relates to a kit for a homogenous detection method for the quantitative or qualitative detection of an analyte in an assay and adequate reagents therefor, particularly a homogenous binding test. According to the invention, an analyte-specific binding partner R1 comprises more than one specific binding point for a specific binding partner X that is associated with a component of a signal-forming system while a second analyte-specific binding partner R2 comprises more than one specific binding point for a specific binding partner Y which is also associated with a component of a signal-forming system.Type: GrantFiled: January 23, 2013Date of Patent: January 14, 2014Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Carsten Schelp, Michael Trier, Hrair Kirakossian
-
Publication number: 20130344516Abstract: An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ARMET in said sample in vitro.Type: ApplicationFiled: September 10, 2013Publication date: December 26, 2013Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Johann Karl, Julia Riedlinger, Markus Roessler
-
Publication number: 20130331282Abstract: Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) protein and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P protein and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P protein concentrations by measuring the binding of a S1P-specific antibody to S1P protein. The S1P protein disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis.Type: ApplicationFiled: April 18, 2013Publication date: December 12, 2013Inventors: Jung Min Koh, Ghi Su Kim, Seung Hun Lee, Beom Jun Kim
-
Publication number: 20130331329Abstract: The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits.Type: ApplicationFiled: February 24, 2012Publication date: December 12, 2013Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: John Robert Pollard, Peter B. Crino
-
Publication number: 20130316962Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: April 9, 2013Publication date: November 28, 2013Applicant: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Arne Skerra, Andreas Eichinger, Hyun-Jin Kim
-
Publication number: 20130295593Abstract: Vitamin D binding proteins (DBP), in particular truncated DBP and mutated, truncated DBP, as well as fusion proteins thereof, nucleic acid molecules encoding same, vectors, host cells, and methods, kits and solid supports for determining the total amount of 25-hydroxy vitamin D2 and 25-hydroxy vitamin D3 in a test sample.Type: ApplicationFiled: December 23, 2012Publication date: November 7, 2013Inventors: Christian Beckert, Susan E. Brophy, Jonathan Grote, Dagang Huang, Jan Schultess, Bailin Tu
-
Publication number: 20130295592Abstract: Methods and reagents are disclosed for determining a total amount of an analyte in an unknown sample suspected of containing the analyte in the presence of endogeneous interfering substances. The methods involve measuring an amount [Y] of the portion of the analyte in the unknown sample that is bound by endogeneous binding substances employing an assay for the analyte. An amount [Z] of analyte in the unknown sample that is not bound by endogeneous binding substances is determined by the formula: [Z]=a[Y]+b, wherein “a” and “b” are predetermined by conducting the assay on samples containing known amounts of the analyte but substantially free from endogeneous interfering substances. Adding [Y] and [Z] yields the total amount [X] of the analyte in the unknown sample.Type: ApplicationFiled: May 7, 2012Publication date: November 7, 2013Applicant: Siemens Healthcare Diagnostices Inc.Inventor: Tie Quan Wei
-
Publication number: 20130288279Abstract: Provided herein are monoclonal antibodies with a high binding affinity to isoforms of alpha 1-antitrypsin (A1AT), hybridoma cells producing the same, and their uses in diagnosing and/or detecting endometriosis from a serum sample of a subject suspicious of having endometriosis or a subject under health examination.Type: ApplicationFiled: July 15, 2013Publication date: October 31, 2013Inventors: Wei-Chung YANG, Hwei-Jiung WANG, Shui-Tsung CHEN, Ken-Fen LU, Ming-Chi PENG
-
Publication number: 20130287693Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: SHA MI, JOHN MCCOY, R. BLAKE PEPINSKY, DANIEL H.S. LEE
-
Patent number: 8569001Abstract: A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody.Type: GrantFiled: April 21, 2011Date of Patent: October 29, 2013Assignees: Seikagaku Corporation, Saint Louis UniversityInventors: Kazuo Okamura, Shuichi Miyaura, Shunji Tomatsu
-
Publication number: 20130280740Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.Type: ApplicationFiled: June 14, 2013Publication date: October 24, 2013Inventors: Murthy V.S.N. Yerramilli, Mahalakshmi Yerramilli, Michael Atkinson, Kwok Kam Yeung
-
Publication number: 20130273580Abstract: Improved ELISA assay formats are described that provide for effective measurement of desmosine, an elastin degradation product, in urine samples. The urine samples can be effectively introduced into the assay with little or no sample preparation. The competitive ELISA assay based on high titer polyclonal antibodies is suitable for commercial application. Desirable antibodies can be generated using desmosine bound to a protein or the like using a protein crosslinking agent. The desmosine assay are found to be useful for the diagnosis of aortic aneurysms in which desmosine levels of patients with aortic aneurysms have been found to be significantly elevated relative to a control group.Type: ApplicationFiled: April 17, 2012Publication date: October 17, 2013Inventors: Barry C. Starcher, Marina A. Durward, Laurie Lynch, Matthew F. Ogle
-
Publication number: 20130273581Abstract: The invention relates to haptens, immunogens and secondary immunoreactive agents, to the use thereof for producing wide-spectrum antibodies against quinolone-type antibiotics, to the application thereof to immunochemical analysis techniques, and to a kit enabling the detection of said antibiotics in biological samples from food products of animal origin.Type: ApplicationFiled: November 21, 2011Publication date: October 17, 2013Inventors: Maria Pilar Marco Colas, Francisco José Sánchez Baeza, Daniel González Pinacho
-
Publication number: 20130260402Abstract: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.Type: ApplicationFiled: March 13, 2013Publication date: October 3, 2013Inventors: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., The United States of America as represented by the Secretary of the Department of Health and Human
-
Publication number: 20130243756Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: February 19, 2013Publication date: September 19, 2013Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
-
Publication number: 20130209474Abstract: The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways.Type: ApplicationFiled: April 16, 2013Publication date: August 15, 2013Applicant: Stowers Institute for Medical ResearchInventor: Stowers Institute for Medical Research
-
Publication number: 20130210040Abstract: It has been demonstrated that the level of sST2 increases in pregnant females suffering from pre-eclampsia. Accordingly, the level of sST2 in a pregnant female can be used to assess risk of developing pre-eclampsia.Type: ApplicationFiled: August 3, 2011Publication date: August 15, 2013Applicant: ISIS INNOVATION LIMITEDInventors: Ian Sargent, Jennifer Southcombe, Ingrid Granne
-
Patent number: 8507214Abstract: The present invention provides an ELISA kit for detecting lincomycin comprising a coating antigen and an enzyme labeled reagent, wherein the coating antigen is selected from the group consisting of a lincomycin hapten-carrier protein conjugate, a lincomycin antibody and a lincomycin anti-antibody; when the coating antigen is the lincomycin hapten-carrier protein conjugate, the enzyme labeled reagent is an enzyme-labeled lincomycin anti-antibody; when the coating antigen is the lincomycin antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and when the coating antigen is the lincomycin anti-antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and the lincomycin hapten is obtained through the condensation reaction between lincomycin and succinic anhydride.Type: GrantFiled: September 27, 2008Date of Patent: August 13, 2013Assignee: Beijing Kwinbon Biotechnology Co., Ltd.Inventors: Fangyang He, Yuping Wan, Caiwei Feng, Zhengmiao Zhao, Caimao Feng, Shanliang Wang, Xiaoqin Luo, Xiaobin Ma
-
Publication number: 20130203092Abstract: The present invention provides methods, compositions, apparatus, and kits for assessing glycoforms of proteins as a biomarker for disease. A purified recombinant form of lectin is used as a detector molecule to specifically label target sugars expressed in disease states. The high affinity of recombinant lectin allows for automation of assays that would be used in the diagnosis of diseases such as, but not limited to, cancer or liver disease.Type: ApplicationFiled: February 3, 2012Publication date: August 8, 2013Applicant: INSTITUTE FOR HEPATITIS AND VIRUS RESEARCHInventors: Patrick Robert ROMANO, Anand MEHTA, Timothy M. Block
-
Publication number: 20130203616Abstract: Methods and kits for detecting antibodies (e.g., anti-drug antibodies) specific for abundant body fluid components are provided. Such methods and kits permit the detection of, for example, human serum albumin in human body fluids, such as blood, plasma and serum.Type: ApplicationFiled: April 26, 2011Publication date: August 8, 2013Applicant: MERRIMACK PHARMACEUTICALSInventors: Sam Shenghua Song, Arthur J. Kudla, Mark David Moody
-
Patent number: 8501427Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.Type: GrantFiled: January 23, 2008Date of Patent: August 6, 2013Assignee: University College Cardiff Consultants LimitedInventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
-
Publication number: 20130183317Abstract: A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.Type: ApplicationFiled: March 13, 2013Publication date: July 18, 2013Applicant: Temple University of the Commonwealth System of Higher EducationInventor: Temple University of the Commonwealth System of Higher Education
-
Patent number: 8481332Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.Type: GrantFiled: January 24, 2011Date of Patent: July 9, 2013Assignee: Stichting Voor de Technische WetenshappenInventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn